Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations

Mitochondrial oxidative stress is the achille’s heel of melanoma cells resistant to Braf-mutant inhibitor

(2015) Paola Corazao-Rozas et al.   Oncotarget

The cytotoxicity of the anticancer drug elesclomol is due to oxidative stress indirectly mediated through its complex with Cu(II)

(2014) Brian B. Hasinoff et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

Copper is required for oncogenic BRAF signalling and tumorigenesis

(2014) Donita C. Brady et al.   NATURE

Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells

(2013) Alexander Roesch et al.   CANCER CELL

Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma

(2013) Steven J. O'Day et al.   JOURNAL OF CLINICAL ONCOLOGY

Resistance to RAF Inhibitors Revisited

(2013) Edward Hartsough et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Phenformin enhances the therapeutic benefit of BRAFV600E inhibition in melanoma

(2013) P. Yuan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

(2013) H. Shi et al.   Cancer Discovery

Inactivation of the HIF-1 /PDK3 Signaling Axis Drives Melanoma toward Mitochondrial Oxidative Metabolism and Potentiates the Therapeutic Activity of Pro-Oxidants

(2012) J. Kluza et al.   CANCER RESEARCH

Importance of glycolysis and oxidative phosphorylation in advanced melanoma

(2012) Jonhan Ho et al.   Molecular Cancer

Mitochondrial Electron Transport Is the Cellular Target of the Oncology Drug Elesclomol

(2012) Ronald K. Blackman et al.   PLoS One

Mitochondrial Respiration - An Important Therapeutic Target in Melanoma

(2012) Michelle Barbi de Moura et al.   PLoS One

A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth

(2010) Alexander Roesch et al.   CELL

Metabolic flexibility and cell hierarchy in metastatic cancer

(2010) Michael V. Berridge et al.   MITOCHONDRION

Phase II, Randomized, Controlled, Double-Blinded Trial of Weekly Elesclomol Plus Paclitaxel Versus Paclitaxel Alone for Stage IV Metastatic Melanoma

(2009) Steven O'Day et al.   JOURNAL OF CLINICAL ONCOLOGY

Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

(2009) M. G. Vander Heiden et al.   SCIENCE

Elesclomol induces cancer cell apoptosis through oxidative stress

(2008) J. R. Kirshner et al.   MOLECULAR CANCER THERAPEUTICS